SSC
DGX icon

Syverson Strege & Co’s Quest Diagnostics DGX Stock Holding History

Syverson Strege & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$1.84K – 208
2023
Q1 		$1.84K Buy
+13
New +$1.86K ﹤0.01% 505
2021
Q4 		– Sell
-39
Closed -$6K – 345
2021
Q3 		$6K Buy
+39
New +$5.71K ﹤0.01% 293

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Syverson Strege & Co's DGX Position: Q2 2023 in Review

Syverson Strege & Co sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 13 shares — an estimated $1.84K sold.

Syverson Strege & Co first reported a position in DGX in Q3 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

  • Syverson Strege & Co reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 13 Quest Diagnostics shares in Q2 2023, an estimated $1.84K.
  • Syverson Strege & Co first reported a position in Quest Diagnostics in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Quest Diagnostics position peaked at $6K in Q3 2021.
  • 818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.